qingdao sigma chemical semaglutide ( Other Name ) | China | Manufacturer Buy Semaglutide - 5mg |

GLP-1 receptor agonist studied for metabolic & glycemic research

Consumers would be spending in other categories, though, so the household microeconomics of the GLP-1s could increase demand for new clothing, gym memberships, and perhaps even tourism if the individual feels more mobile to travel

Reddys, Cipla, Lupin, Alkem, Sun Pharma, and Natco are racing to introduce affordable alternatives to Ozempic and Wegovy

GLP-1s are proving their value well beyond the scale, with benefits ranging from improved glycemic control and reduced cardiovascular risk to better mobility and quality of life

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution